Investigational drugs in recent clinical trials for treatment-resistant depression
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The authors describe the medications for treatment-resistant depression (TRD) in phase II/III of clinical development in the EU and USA and provide an opinion on how current treatment can be improved in the near future. Areas covered: Sixty-two trials were identified in US and EU clinical trial registries that included six investigational compounds in recent phase III development and 12 others in recent phase II clinical trials. Glutamatergic agents have been the focus of many studies. A single intravenous dose of the glutamatergic modulator ketamine produces a robust and rapid antidepressant effect in persons with TRD; this effect continues to remain significant for 1 week. This observation was a turning point that opened the way for other, more selective glutamatergic modulators (intranasal esketamine, AVP-786, AVP-923, AV-101, and rapastinel). Of the remaining compounds, monoclonal antibodies open highly innovative therapeutic options, based on new pathophysiological approaches to depression. Expert commentary: Promising new agents are emerging for TRD treatment. Glutamatergic modulators likely represent a very promising alternative to monoaminergic antidepressant monotherapy. We could see the arrival of the first robust and rapid acting antidepressant drug in the near future, which would strongly facilitate the ultimate goal of recovery in persons with TRD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Overweight, Obesity, and Depression: A Systematic Review and Meta-analysis of Longitudinal Studies
Luppino, F. S., de Wit, L. M., Bouvy, P. F., Stijnen, T., Cuijpers, P., Penninx, B. W. J. H., & Zitman, F. G. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.2 · Cited by 4,322
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609 · cited 3×
“A recent study in mice showed that a ketamine metabolite is essential for its antidepressant effects [57,59].”
BackgroundCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 6×
“[100] conducted an open-label trial of adjunctive psilocybin in 12 patients with MDD who had failed to respond to at least”
BackgroundInfluentialFerrari, A. J., Somerville, A. J., Baxter, A. J., Norman, R., Patten, S. B., Vos, T., & Whiteford, H. A. (2013) · Psychological Medicine · doi:10.1017/s0033291712001511 · Cited by 1,230
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies.
Valkanova, V., Ebmeier, K. P., & Allan, C. L. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.004 · Cited by 972 · cited 1×
“In 2013, a meta-analysis of three studies found that raised plasma levels of IL-6 had a small and statistically borderline association with the subsequent development of depressive symptoms [125].”
BackgroundKöhler, O., Benros, M. E., Nordentoft, M., Farkouh, M. E., Iyengar, R. L., Mors, O., & Krogh, J. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1611 · Cited by 941
Khandaker, G. M., Pearson, R. M., Zammit, S., Lewis, G., & Jones, P. B. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1332 · Cited by 846 · cited 1×
“In another study, high IL-6 blood levels in childhood were found to be associated with an increased risk of developing depression in young adulthood [126], but not in a prospective analysis of 4,756 women (who were depression free up to 1996) over a follow-up of 6–18 years [95].”
BackgroundTreatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525 · cited 4×
“One special issue was maintaining the antidepressant efficacy of ketamine over the longer term [35,36,38,41,51,53,54,140].”
BackgroundInfluentialSingh, J. B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., Tadic, A., Sienaert, P., Wiegand, F., Manji, H., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.018 · Cited by 466
Kapur, S., & Seeman, P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001093 · Cited by 459 · cited 1×
“as a partial agonist at dopamine D2 receptors and as a dopamine reuptake inhibitor [43,44,47,57].”
BackgroundTreatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
McIntyre, R. S., Filteau, M.-J., Martin, L., Patry, S., Carvalho, A., Cha, D. S., Barakat, M., & Miguelez, M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.043 · Cited by 421 · cited 3×
“First-line adjunctive medications are atypical antipsychotics [1,7], lithium [19], and thyroid hormone [20].”
BackgroundMcGirr, A., Berlim, M. T., Bond, D. J., Fleck, M. P., Yatham, L. N., & Lam, R. W. (2015) · Psychological Medicine · doi:10.1017/s0033291714001603 · Cited by 373
Prescription of long-acting opioids and mortality in patients with chronic noncancer pain
Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2016) · JAMA · doi:10.1001/jama.2016.7789 · Cited by 369
R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
Zhang, J.-C., Li, S.-X., & Hashimoto, K. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.033 · Cited by 357
Buprenorphine Treatment of Refractory Depression
Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502000-00008 · Cited by 346
Deakin, J. F. W., Lees, J., McKie, S., Hallak, J. E. C., Williams, S. R., & Dursun, S. M. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.37 · Cited by 311 · cited 4×
“Animal studies showed that the rapid antidepressant action of ketamine is associated with synapse formation in the medial PFC, an effect likely due to an increase in brain-derived neurotrophic factor (BDNF) [143,144].”
BackgroundInfluentialJudd, L. L., Schettler, P. J., Solomon, D. A., Maser, J. D., Coryell, W., Endicott, J., & Akiskal, H. S. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.06.014 · Cited by 293 · cited 1×
“impaired social functioning because of sustained depressive symptoms [152] and functional outcomes do not always correspond to symptom-based outcomes [153].”
BackgroundThe timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments
Machado-Vieira, R., Baumann, J., Wheeler-Castillo, C., Latov, D., Henter, I. D., Salvadore, G., & Zarate, C. A. (2010) · Pharmaceuticals · doi:10.3390/ph3010019 · Cited by 263
Self-citationZarate, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N. E., Smith, M. A., & Luckenbaugh, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.019 · Cited by 255
Self-citationDuman, R. S. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.1/rduman · Cited by 249 · cited 1×
“and a loss of synaptic connections, particularly in the PFC and hippocampus (for review, see ref [143].”
BackgroundSanacora, G., Smith, M. A., Pathak, S., Su, H.-L., Boeijinga, P. H., McCarthy, D. J., & Quirk, M. C. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.130 · Cited by 236 · cited 1×
“In preliminary RCTs, single or multiple infusions of AZD6765 exhibited antidepressant efficacy without psychotomimetic or dissociative side effects [88].”
BackgroundFava, M., Memisoglu, A., Thase, M. E., Bodkin, J. A., Trivedi, M. H., de Somer, M., Du, Y., Leigh-Pemberton, R., DiPetrillo, L., Silverman, B., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15070921 · Cited by 232 · cited 4×
“Background ALKS 5461 (Alkermes, USA and Ireland) is a combination drug formulation of buprenorphine and the μ-opioid antagonist samidorphan [71,72].”
BackgroundInfluentialCitrome, L. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.07.2174 · Cited by 226
Self-citationIbrahim, L., DiazGranados, N., Jolkovsky, L., Brutsche, N., Luckenbaugh, D. A., Herring, W. J., Potter, W. Z., & Zarate, C. A. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d70d6 · Cited by 220 · cited 1×
“[83] suggested antidepressant efficacy for CERC-301 in TRD”
BackgroundSelf-citationMiyaoka, T., Wake, R., Furuya, M., Liaury, K., Ieda, M., Kawakami, K., Tsuchie, K., Taki, M., Ishihara, K., Araki, T., et al. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.02.002 · Cited by 212
Cummings, J. L., Lyketsos, C. G., Peskind, E. R., Porsteinsson, A. P., Mintzer, J. E., Scharre, D. W., De La Gandara, J. E., Agronin, M., Davis, C. S., Nguyen, U., et al. (2015) · JAMA · doi:10.1001/jama.2015.10214 · Cited by 209
PRESKORN, S., MACALUSO, M., MEHRA, D. V., ZAMMIT, G., MOSKAL, J. R., & BURCH, R. M. (2015) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000462606.17725.93 · Cited by 193
Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Augustine, C., Zhang, P., McQuade, R. D., Carson, W. H., Nyilas, M., Sanchez, R., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09688 · Cited by 182 · cited 1×
“on a clinical development program that included two acute phase pivotal Phase III placebo-controlled trials [110,111].”
MethodKetamine as a Novel Antidepressant: From Synapse to Behavior
Murrough, J. W. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.244 · Cited by 172
Evaluation of Opioid Modulation in Major Depressive Disorder
Ehrich, E., Turncliff, R., Du, Y., Leigh-Pemberton, R., Fernandez, E., Jones, R., & Fava, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.330 · Cited by 169 · cited 3×
“Background ALKS 5461 (Alkermes, USA and Ireland) is a combination drug formulation of buprenorphine and the μ-opioid antagonist samidorphan [71,72].”
BackgroundIrwin, S. A., Iglewicz, A., Nelesen, R. A., Lo, J. Y., Carr, C. H., Romero, S. D., & Lloyd, L. S. (2013) · Journal of Palliative Medicine · doi:10.1089/jpm.2012.0617 · Cited by 167
Bodkin, J. A., Lasser, R. A., Wines, J. D., Gardner, D. M., & Baldessarini, R. J. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0401 · Cited by 159
Chandler, G. M., Iosifescu, D. V., Pollack, M. H., Targum, S. D., & Fava, M. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00102.x · Cited by 158 · cited 6×
“Treatment resistance to AD-ST will be assessed with the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (MGH-ATRQ) [124].”
MethodInfluentialOlin, B., Berry, Broglio, Bunker, Jayewardene, & Rush (2013) · Medical Devices: Evidence and Research · doi:10.2147/mder.s41017 · Cited by 152
Li, C., Chen, M., Lin, W., Hong, C., Yang, B., Liu, R., Tu, P., & Su, T. (2016) · Human Brain Mapping · doi:10.1002/hbm.23085 · Cited by 152 · cited 4×
“Animal studies showed that the rapid antidepressant action of ketamine is associated with synapse formation in the medial PFC, an effect likely due to an increase in brain-derived neurotrophic factor (BDNF) [143,144].”
BackgroundInfluentialDextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
Nguyen, L., Thomas, K. L., Lucke-Wold, B. P., Cavendish, J. Z., Crowe, M. S., & Matsumoto, R. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.016 · Cited by 141 · cited 1×
“Dextromethorphan is a noncompetitive NMDA receptor antagonist and σ1-receptor agonist, commonly used antitussive compound [113,114] (for σ1-receptors in depression, see references [115,116]).”
BackgroundDefining Treatment-Resistant Depression: A Comprehensive Review of the Literature
Trevino, K., McClintock, S. M., Fischer, N. M., Vora, A., & Husain, M. M. (2014) · Annals of Clinical Psychiatry · doi:10.1177/104012371402600310 · Cited by 130 · cited 1×
“diagnostic tools are sometime lacking [3].”
Ionescu, D. F., Swee, M. B., Pavone, K. J., Taylor, N., Akeju, O., Baer, L., Nyer, M., Cassano, P., Mischoulon, D., Alpert, J. E., et al. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10056 · Cited by 126
Durgam, S., Earley, W., Guo, H., Li, D., Németh, G., Laszlovszky, I., Fava, M., & Montgomery, S. A. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10070 · Cited by 125 · cited 4×
“One phase II RCT [76] evaluated the efficacy and safety of cariprazine as adjunctive therapy in patients with MDD who”
BackgroundMethodInfluentialSequenced Treatment Alternatives to Relieve Depression (STAR*D): Part 2: Study Outcomes
Howland, R. H. (2008) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20081001-05 · Cited by 115
Depressive symptoms during buprenorphine treatment of opioid abusers
Kosten, T. R., Morgan, C., & Kosten, T. A. (1990) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(90)90035-o · Cited by 110
Borges, S., Chen, Y.-F., Laughren, T. P., Temple, R., Patel, H. D., David, P. A., Mathis, M., Unger, E., Yang, P., & Khin, N. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08722 · Cited by 109
Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan
Nguyen, L., Robson, M. J., Healy, J. R., Scandinaro, A. L., & Matsumoto, R. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089985 · Cited by 99 · cited 1×
“Dextromethorphan is a noncompetitive NMDA receptor antagonist and σ1-receptor agonist, commonly used antitussive compound [113,114] (for σ1-receptors in depression, see references [115,116]).”
BackgroundCoplan, J. D., Gopinath, S., Abdallah, C. G., & Berry, B. R. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00189 · Cited by 90
Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression
Kim, Y.-K., & Na, K.-S. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.03.009 · Cited by 84
Treatment-emergent adverse events associated with atypical antipsychotics
Cha, D. S., & McIntyre, R. S. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.656590 · Cited by 68
Citrome, L. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12714 · Cited by 63
Self-citationCitrome, L., Stensbøl, T. B., & Maeda, K. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1086269 · Cited by 63 · cited 2×
“Background Brexpiprazole (Rexulti®, Otsuka, Japan) is an atypical antipsychotic, acting as a partial agonist at dopamine D2 receptors and as an antagonist at 5-HT2A receptors [73,74].”
BackgroundSelf-citationLam, R. W., Parikh, S. V., Michalak, E. E., Dewa, C. S., & Kennedy, S. H. (2015) · Annals of Clinical Psychiatry · doi:10.1177/104012371502700209 · Cited by 62 · cited 2×
“impaired social functioning because of sustained depressive symptoms [152] and functional outcomes do not always correspond to symptom-based outcomes [153].”
BackgroundDean, O. M., Maes, M., Ashton, M., Berk, L., Kanchanatawan, B., Sughondhabirom, A., Tangwongchai, S., Ng, C., Dowling, N., Malhi, G. S., et al. (2014) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2014.12.3.180 · Cited by 58 · cited 1×
“pants to evaluate the antidepressant efficacy of minocycline in patients with TRD (NCT02263872 [102]; see also [104]).”
BackgroundNorelli, L. J., Smith, H. S., Sher, L., & Blackwood, T. A. (2013) · ijamh · doi:10.1515/ijamh-2013-0069 · Cited by 30
Buprenorphine and the treatment of depression, anxiety, non-suicidal self-injury, and suicidality
Sher, L. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12577 · Cited by 6
Cited by
The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain
Sheng, J., Liu, S., Wang, Y., Cui, R., & Zhang, X. (2017) · Neural Plasticity · doi:10.1155/2017/9724371 · Cited by 775
Prognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
Self-citationRecognizing Depression from the Microbiota–Gut–Brain Axis
Liang, S., Wu, X., Hu, X., Wang, T., & Jin, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061592 · Cited by 380
Bipolar depression: a major unsolved challenge
Baldessarini, R. J., Vázquez, G. H., & Tondo, L. (2020) · International Journal of Bipolar Disorders · doi:10.1186/s40345-019-0160-1 · Cited by 235
Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide
Duman, R. S. (2018) · F1000Research · doi:10.12688/f1000research.14344.1 · Cited by 207
“…site is AV-101, a prodrug (L-4-chlorokynurenine) that is transported into the brain where it is converted to 7-chlorokynurenic acid, a potent antagonist of the glycine B coagonist site of the NMDA receptor 62 ; AV-101 is in phase II clinical trials and has received fast-track status from the FDA.”
Background
Metadata
- Authors
- Garay, R. P., Zarate, C. A., Charpeaud, T., Citrome, L., Correll, C. U., Hameg, A., & Llorca, P.-M.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2017-01-29
- Volume
- 17
- Issue
- 6
- Pages
- 593-609
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2573419808
- Cited by
- 74
- References
- 61
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.